Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Herceptin helps women with multiple chromosomes containing HER2 gene

The targeted therapy Herceptin helps women with HER2+ type of breast cancer independent of whether patients have extra copies of chromosome 17, home to the HER2 gene which produces the HER2 protein that fuels cancer growth.

17 Dec 2007

Vaccinex receives new European patent for antibody discovery technology

Vaccinex, Inc. has announced the award of a key European patent (European Patent No. 1340088) for its antibody discovery technology platform, branded as ActivMab Technology.

3 Dec 2007

Morphotek issued new U.S patent for method to enhance the affinity of monoclonal antibodies

Morphotek, Inc., a subsidiary of Eisai Co., Ltd. has announced the issuance of United States Patent No. 7,235,643 B2 (the "643" patent).

19 Nov 2007

Cancers successfully treated by targeting the viruses that cause them

Researchers at the Albert Einstein College of Medicine of Yeshiva University have shown for the first time that cancers can be successfully treated by targeting the viruses that cause them.

31 Oct 2007

Light activated magic bullets zap out cancers

Scientists in Britain believe they may be able to use ultra-violet light to render cancer-fighting drugs far more effective.

30 Oct 2007

Preventing lung scarring may extend lives of lung cancer patients

Researchers have found that using a special type of drug called a pharmaceutical monoclonal antibody to block the integrin beta6-TGF-beta pathway prevents a serious side effect of radiation therapy for lung cancer patients – pulmonary fibrosis (scarring of the lungs), thereby extending patients' lives and improving their quality of life, according to a study presented at the Plenary I session on October 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.

29 Oct 2007

Emerging cancer therapies and novel targets

What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.

25 Oct 2007

Breakthrough reveals important human receptor structure that will aid drug development

Scientists at the MRC Laboratory of Molecular Biology (LMB) in Cambridge have obtained the first clear images of the proteins that relay vital messages to cells.

22 Oct 2007

Lilly and MacroGenics to develop and commercialize teplizumab

Eli Lilly and Company and MacroGenics, Inc. have announced that the two companies have entered into a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases.

19 Oct 2007

Abbott creates one molecule with two antibody functions

Abbott has reported that its scientists are the first to discover a proprietary technology that combines the function and specificity of two or more monoclonal antibodies (mAbs) into one molecular entity that demonstrates drug-like properties and manufacturing feasibility.

19 Oct 2007

Breast cancer awareness calls for cardiovascular awareness

Women who overcome breast cancer have every reason to celebrate. But a heart filled with joy may also be a heart damaged by life-saving cancer therapies, a growing body of research shows.

12 Oct 2007

Medimmune announces phase 2 safety data for anti-RSV antibody

MedImmune, Inc. has announced results from two important studies presented at the 2007 Infectious Diseases Society of America (IDSA) 45th Annual Meeting adding to the body of knowledge about respiratory syncytial virus (RSV).

4 Oct 2007

Promising trial results show biologic therapy ustekinumab significantly improved psoriasis

The first reported findings from an international, Phase 3 study showed that more than two-thirds of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the Psoriasis Area and Severity Index (PASI 75).

4 Oct 2007

Experimental drug pertuzumab boosts survival in recurrent ovarian cancer

New clinical data showed an experimental drug called pertuzumab prolonged the survival time for women with recurrent ovarian cancer, a University of Alabama at Birmingham doctor said recently.

27 Sep 2007

Trop-2 new target for anti-tumour therapy in cancer

Italian scientists announced (Monday September 24) that they have found a new and promising target for anti-tumour therapy in cancer.

25 Sep 2007

FDA licenses 15 new blood typing tests

The U.S. Food and Drug Administration today licensed 15 new blood typing tests that were previously unavailable in the United States.

17 Sep 2007

Radiation and drug combo helps boost efficacy of lung-cancer treatment

Combining radiation therapy with a drug that helps destroy blood vessels nourishing malignant tumors has been shown in mice to be significantly more effective in treating lung cancer than either approach alone, researchers at UT Southwestern Medical Center have found.

5 Sep 2007

Discovery of monoclonal antibodies which may make a successful Hepatitis C vaccine a reality

Hepatitis C Virus (HCV) infects up to 500,000 people in the UK alone, many of the infections going undiagnosed.

4 Sep 2007

Radiation and drug combo helps boost efficacy of lung cancer treatment

3 Sep 2007

FDA grants orphan drug designation to TREANDA

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's investigational therapy, TREANDA (bendamustine HCl), for the treatment of chronic lymphocytic leukemia (CLL).

29 Aug 2007